Type of paraffin, choice of glass slides and other factors can influence your DNA yield #CBCIII #whypathologistsmatter Sinchita Roy MD PhD

Dara Aisner discusses the financial and regulatory issues behind molecular testing -- I think many oncologists not aware of many of the significant issues that will determine the accessibility of genomic info that we use to treat patients #CBCIII

Dr. Richard Brown from Memorial Hermann shares their experiences on, "Biomarker testing in community practice" #CBClll Adam L. Booth, MD @PhilipTCagle Sinchita Roy MD PhD Genevieve Crane, MD, PhD

Dr. Richard Brown discusses how clinical practice guidelines help with building consensus and standardization #CBCIII

Dr. Teri Longacre Stanford Pathology with updates on endometrial cancer biomarker testing, highlighting MMR IHC interpretation problems and a reminder to always have an internal control #CBCIII

POLE ultramutated, a newly identified subset of endometrial cancer discovered using molecular not histologic markers. Tons of mutations, including some MSI unstable, better prognosis #CBCIII Dr Teri Longacre

Molecular subtypes of gastro-esophageal cancer correlate with anatomic location. Of these, EBV+ has best prognosis — Dr. Kay Washington #CBCIII

Be careful not to overstate the likelihood of Lynch Syndrome Rhonda Yantiss #CBCIII #gipath

What are the controversies in head and neck cancer HPV guidelines? Dr. Mary Schwartz discusses development of CAPathologists guidelines now published in Arch Pathol Lab Med and endorsed by ASCO #CBCIII

Late in the afternoon and still a full house at #CBCIII - a true testament to the quality of presentations @PhilipTCagle Genevieve Crane, MD, PhD

MMR interp problems - good things to remember #CBCIII @PhilipTCagle Genevieve Crane, MD, PhD @

Personal tweet: my shoutout from Dr. Mary Schwartz means a lot. I put in a LOT of work to help experts develop our guidelines and to be acknowledged at meeting like #CBCIII is an honor. I get to work with best around the world!

Great things happening at #CBCIII, my personal favorite quote of the day: “#1 side effect of HPV vaccination is pain at injection site, and that will go away, get your kids vaccinated” - the great Dr Mary Schwartz. @PhilipTCagle Genevieve Crane, MD, PhD Sinchita Roy MD PhD Eric Bernicker MD FASCO

Dr. Neal Lindeman of Brigham and Women's Hospital discussing the updated Lung Biomarkers Guideline CAPathologists Association for Molecular Pathology IASLC @PhilipTCagle Eric Bernicker MD FASCO #CBCIII Biomarkers Conference Houston Methodist

Sequencing challenges for cell free DNA— much lower likely tumor fraction, higher sensitivity of 0.1% required. MGH panel focuses on hotspots, significant validation challenges. Dr. Iafrate #CBCIII

Cell free applications: early detection not yet here and may require ~100 cc of blood; assess significance of radiographic incidentalomas; late stage disease assessment of tissue of origin #CBCIII Dr. Iafrate

Dr. Alan Borczuk explains PD-L1 biomarker testing challenges. #CBCIII

Truer words have never been said.... Dr. Alain Borczuk on PDL1 as a biomarker. #CBCIII Sinchita Roy MD PhD @PhilipTCagle Timothy Craig Allen, MD, JD, FCAP Genevieve Crane, MD, PhD

#CBCIII Superb conference, great speakers, great venue! Look forward to the next one.@PhilipTCagle Sinchita Roy MD PhD Roberto Barrios Genevieve Crane, MD, PhD Timothy Craig Allen, MD, JD, FCAP

Dr. Ross Miller Ross A Miller MD kicks off #TSP2018 with an update on PD-L1 Expression, Role, and Significance in Lung Pathology #pulmpath